These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38832137)

  • 21. Size reduction of gastric fundic gland polyposis by de-escalation of acid-suppressive therapy.
    Kanamori A; Tominaga K; Masuyama H; Ishikawa M; Masuyama S; Kondo M; Kanazawa M; Tanaka T; Yamaura M; Abe K; Watanabe S; Yamamiya A; Abe Y; Goda K; Irisawa A
    DEN Open; 2023 Apr; 3(1):e135. PubMed ID: 35898833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.
    Habu Y; Hamasaki R; Maruo M; Nakagawa T; Aono Y; Hachimine D
    J Gen Fam Med; 2021 Sep; 22(5):237-245. PubMed ID: 34484992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.
    Shibli F; Kitayama Y; Fass R
    Curr Gastroenterol Rep; 2020 Mar; 22(4):16. PubMed ID: 32185589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
    Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
    Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
    Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroesophageal Reflux Disease: Pathophysiology and New Treatment Trends.
    Kasugai K; Ogasawara N
    Intern Med; 2024 Jan; 63(1):1-10. PubMed ID: 36927966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
    Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
    J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.
    Bautista JM; Wong WM; Pulliam G; Esquivel RF; Fass R
    Dig Dis Sci; 2005 Oct; 50(10):1909-15. PubMed ID: 16187196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy of gastroesophageal reflux disease.
    Coron E; Hatlebakk JG; Galmiche JP
    Curr Opin Gastroenterol; 2007 Jul; 23(4):434-9. PubMed ID: 17545782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic yield of ambulatory oesophageal studies on versus off proton pump inhibitors: a systematic review and meta-analysis.
    Ang D; Zheng Q; Shi L; Tack J
    United European Gastroenterol J; 2018 Nov; 6(9):1294-1306. PubMed ID: 30386602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of potassium-competitive acid blockers in the treatment of acid-related digestive diseases].
    Buzás GM
    Orv Hetil; 2023 Dec; 164(50):1967-1973. PubMed ID: 38108833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid.
    Sharma P; Yadlapati R
    Ann N Y Acad Sci; 2021 Feb; 1486(1):3-14. PubMed ID: 33015827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontiers in Endoscopic Treatment for Gastroesophageal Reflux Disease.
    Ota K; Takeuchi T; Higuchi K; Sasaki S; Mori Y; Tanaka H; Hakoda A; Sugawara N; Iwatsubo T; Nishikawa H
    Digestion; 2024; 105(1):5-10. PubMed ID: 37591209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
    Barberio B; Visaggi P; Savarino E; de Bortoli N; Black CJ; Ford AC
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14469. PubMed ID: 36153790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
    Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
    Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.